Acumen Pharmaceuticals (ABOS) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Molecular Partners (MOLN) over the past year, gaining 11.7% versus a gain of 2.7%. Over five years, MOLN leads with a -80.8% price change compared with -84.5% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($151.9 million vs $145.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | MOLN |
|---|---|---|
| Share price | $2.10 | $3.81 |
| Market cap | $151.87M | $145.94M |
| 1-day change | +3.45% | +0.79% |
| YTD return | -0.47% | -12.59% |
| 1-year return | +11.70% | +2.70% |
| 5-year return | -84.50% | -80.76% |
| EPS (TTM) | $-1.56 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $5.36 |
| 52-week low | $1.50 | $3.53 |
| Distance from 52-week high | -41.67% | -28.92% |
| Average volume | 429.73K | 1.19K |
| Shares outstanding | 72.32M | 38.31M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ABOS vs MOLN FAQ
Which is bigger, Acumen Pharmaceuticals or Molecular Partners?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $151.87M compared with $145.94M for Molecular Partners (MOLN).
Which stock has performed better over the past year, ABOS or MOLN?
ABOS returned +11.70% over the past 12 months, compared with +2.70% for MOLN (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.